Tuberculosis Clinical Trial
Official title:
A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS 404 When Administered as Different IC31 Adjuvant Amounts With Different AERAS-404 (HyVac4) Antigen Amounts in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection
Verified date | March 2014 |
Source | Aeras |
Contact | n/a |
Is FDA regulated | No |
Health authority | Finland: Finnish National Agency for Medicines |
Study type | Interventional |
This Phase I study will be conducted as a randomized, double-blind, dose-escalation study in five groups of healthy adult male and female subjects who are BCG-vaccinated, HIV-negative, and have no evidence of tuberculosis infection. Since BCG-vaccinated individuals are the target population for which AERAS 404 might be indicated, AERAS 404 will be administered to individuals already vaccinated with BCG
Status | Completed |
Enrollment | 60 |
Est. completion date | October 2009 |
Est. primary completion date | October 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Has completed written informed consent 2. Is male or female 3. Is age 18 through 45 years on Study Day 0 4. Had BCG vaccination at least 5 years ago, documented through medical history or presence of scar 5. Has general good health, confirmed by medical history and physical examination 6. Has a Body Mass Index (BMI) between 19 and 33 7. Agrees to complete a follow-up period of 182 days as required by the protocol 8. Females: Agrees to avoid pregnancy from 28 days prior to Study Day 0 through the follow-up period of 182 days. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses) must agree to avoid pregnancy using an acceptable method 9. Agrees to avoid elective surgery for the duration of the study 10. Agrees to stay in contact with the investigative site for the study duration 11. Completed simultaneous enrollment in Aeras Vaccine Development Registry protocol Exclusion Criteria: 1. Acute illness on Study Day 0 2. Axillary temperature >=37.5 degrees Celsius on Study Day 0 3. Evidence of significant active infection 4. Used immunosuppressive medication within 42 days before Study Day 0 5. Received immunoglobulin or blood products within 42 days before Study Day 0 6. Received any investigational drug therapy or investigational vaccine within 182 days before Study Day 0 7. Received inactivated influenza vaccine or inactivated tick-borne encephalitis vaccine within 14 days before entry into the study, or any other standard vaccine within 42 days before Study Day 0 8. Current chronic drug therapy including hormone replacement such as thyroxin, insulin 9. History or laboratory evidence of past, present or future possible immunodeficiency state which include any laboratory indication of HIV infection 10. History of allergic disease or reactions, including eczema 11. Previous medical history that may compromise safety of the subject in the study 12. Evidence of new acute illness that may compromise the safety of subject in the study 13. Evidence of chronic hepatitis 14. Inability to discontinue daily medications except contraceptives during study period 15. History of alcohol or drug abuse within past 2 years 16. Tobacco or cannabis smoking three or more days per week 17. Positive urine test for illicit drugs 18. History or evidence of any systemic disease on physical examination 19. History or evidence of active tuberculosis 20. Shared a residence within the last year with a individual on anti-tuberculosis treatment or with culture or smear positive tuberculosis 21. All females: Positive urine pregnancy test during screening 22. Abnormal (per local laboratory parameters) chemistry and hematology parameters 23. QuantiFERON®-TB Gold evidence of Mtb infection 24. Received a tuberculin skin test within 3 months (90 days) prior to Study Day 0 |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Finland | University of Tampere Vaccine Research Clinic | Biokatu | Tampere |
Lead Sponsor | Collaborator |
---|---|
Aeras | Statens Serum Institut |
Finland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety profile of two injections of AERAS 404 at different dose levels of antigen and adjuvant. | Serious Adverse Events (SAE) will be collected on subjects throughout their participation in the study. Solicited and unsolicited adverse events are captured 28 days post each vaccination. The safety profile of AERAS-404 will be summarized by treatment regimen. The number (percentage) of subjects with adverse events will be summarized by MedDRA system organ class (SOC), and preferred term (PT). Additional summaries will present the number (percentage) of subjects with adverse events by severity and by relationship to study vaccine. | Total duration of study follow up for all subjects is 182 days. | Yes |
Secondary | Immunogenicity of two injections of AERAS 404 at different dose levels of antigen and adjuvant. | Intracellular cytokine staining will be used to assess immunogenicity. Immune response based on percentages of CD4+ and CD8+ T cells that produced one, two, or three cytokines (IFN-?, TNF-a, and/or IL-2) in response to stimulation with one of 2 antigenic peptide pools (Ag85B and TB10.4) derived from and representing the entire amino acid sequences of the mycobacterial antigens Ag85B and TB10.4, respectively. | Immunogenicity was evaluated from blood collected at Study Days 0, 7, 14, 28, 56, 63, 70, 84, and 182. For all subjects, a QuantiFERON-TB Gold test was performed during screening and at Study Day 182 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |